Our Technologies

Dr Tarik Möröy

lncRNA overexpression is significantly effective at inhibiting the growth of myeloid leukemia.

National Phase Patent Application– Dr. André Veillette

A novel immune check point inhibitor targeting SLAMF6 to boost immune activation and supress tumor growth.

Publication

US Provisional Patent Application – Dr. Gu Hua

A next-generation antibody therapy for multiple influenza subtypes, enabled by a scalable platform targeting a transcription factor in B-cells to generate high-affinity, high-titer antibodies.

PCT Patent Application– Dr. Emilia Liana Falcone

A dual diagnostic and therapeutic strategy for severe long covid: blood-based biomarkers for early detection, and target inhibition to alleviate symptoms.

Published Patent WO2024182903 – Dr. André Veillette

Unique cytotoxic activity by targeting human SLAMF7 with antibody sequences that can be used as a bispecific antibody, as an antibody–drug conjugate (ADC), or in CAR-T and CAR-NK cell therapies. 

PCT Patent Application – Dr. Yvan Guindon

Two new antagonists that interfere with E- and P-selectins, offering a controlled and reversible immunosuppressive strategy to mitigate the risks associated with hyperinflammation.

PCT Patent Application – Dr. Gu Hua

CBLs as a biomarker for diagnosing and assessing disease progression in patients with systemic lupus erythematosus (SLE), as well as a therapeutic target. 

US Provisional Patent Application – Dr. Javier Di Noia

Inactivating newly identified enzyme capable of metabolizing cancer drugs markedly improves therapeutic response to gemcitabine & Decitabine.